Skin Problems Due to Treatment with Technology Are Associated with Increased Disease Burden Among Adults with Type 1 Diabetes.

Autor:	Christensen MO; 1 University of Copenhagen, Copenhagen, Denmark.; 2 Steno Diabetes Center Copenhagen, Gentofte, Denmark., Berg AK; 1 University of Copenhagen, Copenhagen, Denmark.; 3 Copenhagen Diabetes Research Center (CPH-DIRECT), Department of Pediatrics, Copenhagen University Hospital, Herlev, Denmark., Rytter K; 2 Steno Diabetes Center Copenhagen, Gentofte, Denmark., Hommel E; 2 Steno Diabetes Center Copenhagen, Gentofte, Denmark., Thyssen JP; 4 Department of Dermatology and Allergy, Copenhagen University Hospital, Hellerup, Denmark., Svensson J; 1 University of Copenhagen, Copenhagen, Denmark.; 3 Copenhagen Diabetes Research Center (CPH-DIRECT), Department of Pediatrics, Copenhagen University Hospital, Herlev, Denmark., Nørgaard K; 2 Steno Diabetes Center Copenhagen, Gentofte, Denmark.; 5 Department of Endocrinology, Copenhagen University Hospital, Hvidovre, Denmark.
Jazyk:	angličtina
Zdroj:	Diabetes technology & therapeutics [Diabetes Technol Ther] 2019 Apr; Vol. 21 (4), pp. 215-221.
DOI:	10.1089/dia.2019.0007
Abstrakt:	Background: In a 4-month follow-up survey, we examined whether treatment with continuous subcutaneous insulin infusion (CSII) and/or continuous glucose monitoring (CGM) in adults with type 1 diabetes was associated with sustained skin problems and whether skin problems were associated with diabetes-related emotional distress. Research Design and Methods: A total of 111 adult patients completed a follow-up questionnaire concerning skin problems as a result of CSII and/or CGM use. The questionnaire included a patient-reported outcome measure, the Problem Areas in Diabetes (PAID) scale. Results: Current visible skin problems caused by CSII or CGM use were reported by 51 (46.0%) participants, in 34 (66.7%) of whom skin problems had been reported more than 4 months earlier. Seventy-two (64.9%) participants reported skin problems as a result of CSII use, whereas 38 (74.5%) reported skin problems owing to CGM use at some time. Itching was the most prevalent complaint. CSII-related itching was associated with a mean PAID score >20 (P = 0.01), and patients with more than one skin problem had an increased PAID score compared with those with one or no skin problems (P = 0.006). Conclusions: More than half patients treated with CSII, CGM, or both had experienced skin problems during 4 months of follow-up that were associated with increased diabetes burden. Skin problems represent a persistent health issue affecting diabetes-specific emotional distress.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu